BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 18830229)

  • 1. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex.
    Mozaffari M; Hoogeveen-Westerveld M; Kwiatkowski D; Sampson J; Ekong R; Povey S; den Dunnen JT; van den Ouweland A; Halley D; Nellist M
    BMC Med Genet; 2009 Sep; 10():88. PubMed ID: 19747374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reliable cell-based assay for testing unclassified TSC2 gene variants.
    Coevoets R; Arican S; Hoogeveen-Westerveld M; Simons E; van den Ouweland A; Halley D; Nellist M
    Eur J Hum Genet; 2009 Mar; 17(3):301-10. PubMed ID: 18854862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
    Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
    Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex.
    Hoogeveen-Westerveld M; Ekong R; Povey S; Karbassi I; Batish SD; den Dunnen JT; van Eeghen A; Thiele E; Mayer K; Dies K; Wen L; Thompson C; Sparagana SP; Davies P; Aalfs C; van den Ouweland A; Halley D; Nellist M
    Hum Mutat; 2012 Mar; 33(3):476-9. PubMed ID: 22161988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex.
    Nellist M; Sancak O; Goedbloed M; Adriaans A; Wessels M; Maat-Kievit A; Baars M; Dommering C; van den Ouweland A; Halley D
    BMC Med Genet; 2008 Feb; 9():10. PubMed ID: 18302728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
    Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
    Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
    Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
    Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large deletion at the TSC1 locus in a family with tuberous sclerosis complex.
    Nellist M; Sancak O; Goedbloed MA; van Veghel-Plandsoen M; Maat-Kievit A; Lindhout D; Eussen BH; de Klein A; Halley DJ; van den Ouweland AM
    Genet Test; 2005; 9(3):226-30. PubMed ID: 16225402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of the TSC2 c.3598C>T (p.R1200W) missense mutation that co-segregates with tuberous sclerosis complex in mildly affected kindreds.
    Wentink M; Nellist M; Hoogeveen-Westerveld M; Zonnenberg B; van der Kolk D; van Essen T; Park SM; Woods G; Cohn-Hokke P; Brussel W; Smeets E; Brooks A; Halley D; van den Ouweland A; Maat-Kievit A
    Clin Genet; 2012 May; 81(5):453-61. PubMed ID: 21332470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
    Kwiatkowski DJ; Manning BD
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex.
    Choi JE; Chae JH; Hwang YS; Kim KJ
    Brain Dev; 2006 Aug; 28(7):440-6. PubMed ID: 16554133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.
    Niida Y; Lawrence-Smith N; Banwell A; Hammer E; Lewis J; Beauchamp RL; Sims K; Ramesh V; Ozelius L
    Hum Mutat; 1999; 14(5):412-22. PubMed ID: 10533067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction.
    Hoogeveen-Westerveld M; Exalto C; Maat-Kievit A; van den Ouweland A; Halley D; Nellist M
    Biochim Biophys Acta; 2010 Sep; 1802(9):774-81. PubMed ID: 20547222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
    Astrinidis A; Henske EP
    Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.